Literature DB >> 19383422

Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover.

Jianping Wang1, Adrian J Dunn, Amanda J Roberts, Hua Zhang.   

Abstract

Animal models are used to decipher the pathophysiology of IFN-alpha-induced psychiatric complications in humans. However, the behavioral effects of IFN-alpha in rodents remain highly controversial. In contrast to homologous IFN-alpha, our recent study revealed that human IFN-alpha, which was used in many previous investigations, had no biological activity in mice. To evaluate the behavioral effects of homologous IFN-alpha in mice, adult C57BL/6J mice were treated with carrier-free murine IFN-alpha and tested on a number of behavioral paradigms. Surprisingly, contrary to previous reports, IFN-alpha treatment decreased the time spent immobile in the forced-swimming test after a single intraperitoneal injection at 2 x 10(6)IU/kg, whereas general locomotor activity was not altered. The elevated plus-maze (EPM) test showed a trend toward an increased anxiety profile in IFN-alpha-treated mice. The tail-suspension and light dark exploration test revealed no difference between IFN-alpha-treated and control animals. Interestingly, neurochemical analysis revealed significantly increased concentrations of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA)/serotonin (5-HT) ratios following IFN-alpha treatment in selected brain regions. Thus, systemic murine IFN-alpha treatment increases swimming time in mice. Increased cerebral serotonin turnover as well as increased tryptophan concentrations, induced by IFN-alpha, implicates serotonergic neurotransmission in behavioral dysfunction caused by this innate immune mediator.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383422      PMCID: PMC2680382          DOI: 10.1016/j.neulet.2009.01.050

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  35 in total

1.  Paroxetine for the prevention of depression induced by high-dose interferon alfa.

Authors:  D L Musselman; D H Lawson; J F Gumnick; A K Manatunga; S Penna; R S Goodkin; K Greiner; C B Nemeroff; A H Miller
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain.

Authors:  M Kamata; H Higuchi; M Yoshimoto; K Yoshida; T Shimizu
Journal:  Eur Neuropsychopharmacol       Date:  2000-03       Impact factor: 4.600

3.  Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.

Authors:  Stefania Bonaccorso; Valentina Marino; Antonella Puzella; Massimo Pasquini; Massimo Biondi; Marco Artini; Cristiana Almerighi; Robert Verkerk; Herbert Meltzer; Michael Maes
Journal:  J Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.153

4.  Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; M Kohno; M Moriyama; K Takasuna
Journal:  Brain Res       Date:  2000-01-10       Impact factor: 3.252

5.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

Authors:  Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

6.  Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.

Authors:  M Yamano; H Yuki; S Yasuda; K Miyata
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

7.  Behavioral despair in mice: a primary screening test for antidepressants.

Authors:  R D Porsolt; A Bertin; M Jalfre
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

8.  Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

Authors:  L Capuron; A Ravaud; P J Neveu; A H Miller; M Maes; R Dantzer
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 9.  Interferon alpha (IFNalpha) and psychiatric syndromes: a review.

Authors:  Martin Schaefer; Marc A Engelbrecht; Oliver Gut; Bernd L Fiebich; Joachim Bauer; Folkhard Schmidt; Heinz Grunze; Klaus Lieb
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-05       Impact factor: 5.067

10.  Dosing schedule-dependent change in the disruptive effects of interferon-alpha on the circadian clock function.

Authors:  Akiko Shinohara; Satoru Koyanagi; Ahmed Mohsen Hamdan; Naoya Matsunaga; Hironori Aramaki; Shigehiro Ohdo
Journal:  Life Sci       Date:  2008-08-24       Impact factor: 5.037

View more
  7 in total

1.  Acute Administration of the Nonpathogenic, Saprophytic Bacterium, Mycobacterium vaccae, Induces Activation of Serotonergic Neurons in the Dorsal Raphe Nucleus and Antidepressant-Like Behavior in Association with Mild Hypothermia.

Authors:  Philip H Siebler; Jared D Heinze; Drake M Kienzle; Matthew W Hale; Jodi L Lukkes; Nina C Donner; Jared M Kopelman; Orlando A Rodriguez; Christopher A Lowry
Journal:  Cell Mol Neurobiol       Date:  2017-11-13       Impact factor: 5.046

2.  Behavioral evaluation of transgenic mice with CNS expression of IFN-alpha by elevated plus-maze and Porsolt swim test.

Authors:  Hua Zhang; Zhanzhuang Tian; Jianping Wang
Journal:  Neurosci Lett       Date:  2010-06-04       Impact factor: 3.046

3.  Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.

Authors:  J C Felger; S W Cole; T W W Pace; F Hu; B J Woolwine; G H Doho; C L Raison; A H Miller
Journal:  Psychol Med       Date:  2011-12-09       Impact factor: 7.723

Review 4.  Immune-neural connections: how the immune system's response to infectious agents influences behavior.

Authors:  Robert H McCusker; Keith W Kelley
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

5.  CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120.

Authors:  Ricky Maung; Melanie M Hoefer; Ana B Sanchez; Natalia E Sejbuk; Kathryn E Medders; Maya K Desai; Irene C Catalan; Cari C Dowling; Cyrus M de Rozieres; Gwenn A Garden; Rossella Russo; Amanda J Roberts; Roy Williams; Marcus Kaul
Journal:  J Immunol       Date:  2014-07-16       Impact factor: 5.422

6.  Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy.

Authors:  Rong Gao; Ming-qiang Kan; Shi-gang Wang; Run-hua Yang; Shao-gang Zhang
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

7.  Minocycline attenuates interferon-α-induced impairments in rat fear extinction.

Authors:  Qiang Bi; Lijuan Shi; Pingting Yang; Jianing Wang; Ling Qin
Journal:  J Neuroinflammation       Date:  2016-06-30       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.